SageView Advisory Group
KRYS icon

SageView Advisory Group’s Krystal Biotech KRYS Stock Holding History

SageView Advisory Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57
Closed -$14.1K – 1594
2025
Q4 		$14.1K Buy
+57
New +$12K ﹤0.01% 1588

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SageView Advisory Group's KRYS Position: Q1 2026 in Review

SageView Advisory Group sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 57 shares — an estimated $14.1K sold.

SageView Advisory Group first reported a position in KRYS in Q4 2025 and held it in 1 quarter. The position peaked at $14.1K in Q4 2025. 368 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • SageView Advisory Group reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 57 Krystal Biotech shares in Q1 2026, an estimated $14.1K.
  • SageView Advisory Group first reported a position in Krystal Biotech in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Krystal Biotech position peaked at $14.1K in Q4 2025.
  • 368 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.